美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SIMPLIFY HEALTH CARE ETF

39.15

+0.53571.39%

盤後：39.150.00000.00%19:30 EDT

成交量：3.60萬

成交額：140.31萬

市值：3.64億

市盈率：- -

高：39.15

開：39.08

低：38.91

收：38.61

52周最高：40.63

52周最低：30.65

股本：930.00萬

流通股本：930.00萬

量比：0.46

換手率：0.39%

股息：0.25

股息率：0.64%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率

諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率

Hims & Hers在澳大利亞推出GLP-1減肥藥及治療方案

不止步於「減肥藥之王」禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道

不止步於「減肥藥之王」禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道

印度糖尿病全球第二多，月費降至14美元，GLP-1減肥藥為何仍賣不動？

华尔街见闻

中國減肥藥研發公司德睿智藥稱AI助力研發時間縮短一半

惠譽評級：美國醫療保健網絡風險日益增加。

減肥藥營銷「戰事」升級：從名人「代言」到老闆下場，藥企在焦慮什麼？

30周狂賣500萬張！GLP-1引爆行情，減肥藥口服時代來臨

Hims & Hers Health次季虧損超預期，轉向品牌減肥藥導致成本上升

美國銀行每年砸2.5億美元支持員工使用GLP-1減肥藥

安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發

环球市场播报

減肥藥重走PD-1老路，「白菜價藥王」要來？

A股減肥藥板塊低開高走，海正藥業漲停，博騰股份升逾4%，翰宇藥業、眾生藥業、皓元醫藥、恒瑞醫藥等個股跟漲。

HCA醫療下調年度營收預期後，醫院運營商股價集體下跌。

「筆帽」專利訴訟背後：減肥藥帶火百億注射筆賽道

創新醫療器械審批有了綠色通道國產醫療器械為全球提供中國方案

減肥藥板塊短線拉升，爭光股份升逾10%

一款「芭比藥」的粉色妙妙之旅

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PINK/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PINK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PINK\",,,,,undefined,":{"symbol":"PINK","market":"US","secType":"STK","nameCN":"SIMPLIFY HEALTH CARE ETF","latestPrice":39.15,"timestamp":1789675200000,"preClose":38.61435,"halted":0,"volume":35952,"hourTrading":{"tag":"盘后","latestPrice":39.15,"preClose":39.15,"latestTime":"19:30 EDT","volume":13,"amount":508.95,"timestamp":1789687806110,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013871786007015444,"floatShares":9300001,"shares":9300001,"eps":0,"marketStatus":"未開盤","change":0.53565,"latestTime":"09-17 16:00:00 EDT","open":39.08,"high":39.15,"low":38.91,"amount":1403119.01688,"amplitude":0.006215,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":38.61435,"sharesOutstanding":7975001,"nav":38.6199,"aum":359269826.52,"dividendRate":0.006416,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.15,"preClose":39.15,"latestTime":"19:30 EDT","volume":13,"amount":508.95,"timestamp":1789687806110,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.456021,"impliedVol":0.0858,"impliedVolPercentile":0.4143},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PINK\",,,,,undefined,":{"symbol":"PINK","floatShares":9300001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.456021,"shares":9300001,"dividePrice":0.2512,"high":39.15,"amplitude":0.006215,"preClose":38.61435,"low":38.91,"week52Low":30.65,"pbRate":"--","week52High":40.63,"institutionHeld":0,"latestPrice":39.15,"eps":0,"divideRate":0.006416,"volume":35952,"delay":0,"ttmEps":0,"open":39.08,"prevYearClose":36.6,"prevWeekClose":38.69,"prevMonthClose":39.31,"prevQuarterClose":39.15,"fiveDayClose":38.56,"twentyDayClose":40.4263,"sixtyDayClose":37.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PINK\",params:#limit:5,,,undefined,":[{"date":"2026-06-25","symbol":"PINK","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-25","defaultRemindTime":1782394200000,"name":"SIMPLIFY HEALTH CARE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-25","currency":"USD","dateTimestamp":1782360000000,"payDate":"2026-06-30"},{"date":"2026-03-26","symbol":"PINK","amount":0.05,"announcedDate":"2026-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-26","defaultRemindTime":1774531800000,"name":"SIMPLIFY HEALTH CARE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-26","currency":"USD","dateTimestamp":1774497600000,"payDate":"2026-03-31"},{"date":"2025-09-25","symbol":"PINK","amount":0.05,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"SIMPLIFY HEALTH CARE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"PINK","amount":0.05,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY HEALTH CARE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"PINK","amount":0.05,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY HEALTH CARE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PINK\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-27","recordDate":"2021-12-28","paymentDate":"2021-12-30","value":0.0117,"currency":"USD"},{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-03-31","value":0.03535,"currency":"USD"},{"executeDate":"2022-06-27","recordDate":"2022-06-28","paymentDate":"2022-06-30","value":0.02945,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.03121,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":0.01698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PINK\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PINK\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665311633","title":"諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311633?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":"诺和诺德在声明中指出，这项名为STEP Young的试验所纳入的全部受试者，在整个研究期间均接受了生活方式干预，包括限制热量摄入和增加体育锻炼。诺和诺德首席科学官马丁·霍尔斯特·兰格表示：“STEP Young试验的积极结果令人振奋，我们看好司美格鲁肽在帮助罹患肥胖的儿童方面的潜力——这些儿童除生活方式调整外，尚需药物治疗以更有效地管理其肥胖状况。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["THNR","CURE","FHLC","XLVI","TRUH","NVOX","PJP","PINK","FXH","NVOC","IYH","MEDI","RSPH","NVOH","BGIA","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311616","title":"諾和諾德(NVO.US)減肥藥拓展低齡市場：STEP Young試驗顯示司美格魯肽顯著降低兒童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311616?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CURE","XLVI","PINK","RSPH","FXH","IYH","BGIA","NBDS","FHLC","MEDI","THNR","TRUH","PJP","NVOC","NVOH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882140","title":"Hims & Hers在澳大利亞推出GLP-1減肥藥及治療方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882140","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882140?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:10","pubTimestamp":1788228656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["JDOC","IYH","PJP","ELIS","FHLC","ELIL","NVOH","LLII","NBDS","FXH","NVOC","CURE","TRUH","XLVI","LLYX","OZEM","PINK","NVOX","MEDI","RSPH","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006809","title":"不止步於「減肥藥之王」 禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006809","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006809?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来计划以高达28.8亿美元的现金收购Merida Biosciences Inc.，加码自身免疫与过敏疾病领域，以摆脱对减重和糖尿病两大支柱业务的过度依赖——正是这两大市场助其登顶全球药企市值之巅。今年以来，礼来掀起并购狂潮，迄今已宣布的交易总额超过200亿美元。5月，礼来还达成协议，以最高38亿美元收购三家疫苗研发企业。截至发稿，礼来盘前跌0.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FXH","NVOC","PJP","NVOH","PINK","CURE","MEDI","RSPH","IYH","NVOX","TRUH","THNR","NBDS","XLVI","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006800","title":"不止步於「減肥藥之王」 禮來(LLY.US)擬最高28.8億美元收購Merida加碼自身免疫賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006800?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FHLC","PINK","TRUH","NVOX","MEDI","NVOH","XLVI","FXH","NBDS","RSPH","THNR","PJP","NVOC","CURE","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663168590","title":"印度糖尿病全球第二多，月費降至14美元，GLP-1減肥藥為何仍賣不動？","url":"https://stock-news.laohu8.com/highlight/detail?id=2663168590","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663168590?lang=zh_tw&edition=fundamental","pubTime":"2026-08-29 05:55","pubTimestamp":1787954138,"startTime":"0","endTime":"0","summary":"印度减肥药市场正在给全球制药行业上一堂关于市场预期的警示课。尽管GLP-1类药物在印度已实现大规模仿制、价格降至每月14美元，销售表现却远逊于预期，揭示出价格之外更深层的文化、社会与监管障碍。截至今年7月，约三十余种仿制GLP-1药物已在印度药房上市。市场冷淡直接冲击了制药行业对印度的增长押注。印度市场本被视为GLP-1药物向美欧以外拓展的重要试验场。","market":"other","thumbnail":"https://static.tigerbbs.com/62df7fa563e423b513600a842a6669e3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/62df7fa563e423b513600a842a6669e3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780608","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","MNDmain","XLVI","NVOC","IYH","ELIS","LLII","FXH","NVOX","ELIL","NBDS","PINK","UUP","NVOH","TRUH","UDN","THNR","OZEM","MEDI","LLYX","CURE","RSPH","JDOC","PJP"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662376416","title":"中國減肥藥研發公司德睿智藥稱AI助力研發時間縮短一半","url":"https://stock-news.laohu8.com/highlight/detail?id=2662376416","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662376416?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 12:03","pubTimestamp":1787717002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","FXH","NVOC","TRUH","THNR","NVOX","RSPH","PINK","PJP","CURE","CHAT","XLVI","ARTY","NBDS","QTOC","AIPO","IYH","NVOH","VTHR","AGIX","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660649212","title":"惠譽評級：美國醫療保健網絡風險日益增加。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660649212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660649212?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 04:43","pubTimestamp":1787085794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLVI","PINK","BK4588","JHMH","CURE","IYH","RSPH","MOAT","PTH","HYLG","BK4585","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490484","title":"減肥藥營銷「戰事」升級：從名人「代言」到老闆下場，藥企在焦慮什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490484","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:59","pubTimestamp":1786964340,"startTime":"0","endTime":"0","summary":"2026年以来，国内减肥药赛道的宣发动作愈发密集且新颖。8月16日，一场银屑病慢病管理公益计划在上海启动，活动聚焦于银屑病与肥胖的关系。背后的支持方是信达生物（1801.HK），该公司拥有已经获批的银屑病创新药匹康奇拜单抗，也手握国内明星GLP-1药物玛仕度肽。将其他疾病与肥胖话题关联起来，此次活动侧面打开了减肥药宣传的新思路。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843343562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843343562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IYH","NBDS","XLVI","PJP","MEDI","CURE","RSPH","FHLC","PINK","TRUH","FXH","NVOC","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658996687","title":"30周狂賣500萬張！GLP-1引爆行情，減肥藥口服時代來臨","url":"https://stock-news.laohu8.com/highlight/detail?id=2658996687","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658996687?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 17:20","pubTimestamp":1786440001,"startTime":"0","endTime":"0","summary":"据开源证券研报，Wegovy口服片剂上市后处方量快速攀升，30周累计突破500万张，有效扩宽了GLP-1药物可及性边界，驱动减重产业链持续高景气。2026年被业内视作GLP-1减肥药的“口服元年”。产业链全面受益随着海外商业化落地持续超预期，全球GLP-1减重市场规模迎来指数级增长。口服GLP-1药物放量带动规模化生产需求激增，海外药企产能逐步承压，持续将生产环节外包至国内优质代工企业。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/11/20260811783677.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/11/20260811783677.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260811/32331742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4590","FXH","NVOC","PJP","BK4144","PINK","CURE","MEDI","GLP","RSPH","IYH","JDOC","TRUH","THNR","NBDS","XLVI","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969925","title":"Hims & Hers Health次季虧損超預期，轉向品牌減肥藥導致成本上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969925","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969925?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 11:46","pubTimestamp":1786419965,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["FHLC","RSPH","PJP","NVOC","MEDI","CURE","FXH","THNR","XLVI","PINK","TRUH","NBDS","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657896386","title":"美國銀行每年砸2.5億美元支持員工使用GLP-1減肥藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2657896386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657896386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:06","pubTimestamp":1786007162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IYF","KBWB","FXH","LU0648001328.SGD","NVOC","BK4588","THNR","BK4534","JDOC","VFH","PINK","GLP","PGF","UYG","LU1280957306.USD","CURE","FHLC","LU0980610538.SGD","TFNS","ELIL","IE00B19Z3B42.SGD","BAC","XLVI","BK4590","LU1506573853.SGD","TRUH","LLYX","LU0170899867.USD","IYG","NBDS","OZEM","IE00BBT3K403.USD","FTXO","PJP","XLF","LLII","LU0053666078.USD","FNCL","LU0130103400.USD","RSPH","IYH","LU0314106906.USD","LU0211331839.USD","LLYZ","LU0106831901.USD","MEDI","IE0001KFT4U8.USD","ELIS","LU1496350171.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657674945","title":"安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2657674945","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657674945?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:11","pubTimestamp":1785877860,"startTime":"0","endTime":"0","summary":"　　$安进$公司于周二美股收盘后公布财报，第二季度强劲药品销售提振公司利润，因此上调了全年预期，但同时表示将终止一款早期减肥疗法的开发。　　这家生物技术公司周二表示，将停止AMG 513的开发，这是一款目前处于1期研究阶段的潜在减肥疗法。安进称，该研究将完成以跟踪已入组受试者。　　随着AMG 513开发的终止，安进在该领域唯一的候选药物是MariTide，该药目前正在进行针对肥胖、2型糖尿病和慢性体重管理等适应症的3期研究。","market":"sg","thumbnail":"https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkz1673958.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CURE","LU0122379950.USD","RSPH","BIB","BK4533","BK4588","PJP","BK4566","IBB","AMGN","LU0320765992.SGD","THNR","TBXU","LU0058720904.USD","PINK","IYH","NBDS","PBE","BK4599","LU2468319806.SGD","IE00BJJMRZ35.SGD","TRUH","LU0289739699.SGD","BBH","IE00BJT1NW94.SGD","BK4139","LU1983299246.USD","IE00B2B36J28.USD","FXH","LU0889565916.HKD","IBBQ","LU0868494617.USD","NVOC","LU1023059063.AUD","BK4534","BK4581","IE0002141913.USD","XLVI","IE0009355771.USD","LU2242652126.USD","MEDI","LU1571399168.USD","LU1061106388.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","SG9999001440.SGD","LU2242646821.SGD","FHLC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874827","title":"減肥藥重走PD-1老路，「白菜價藥王」要來？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874827","media":"健康凯歌","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874827?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 09:23","pubTimestamp":1784683395,"startTime":"0","endTime":"0","summary":"一场减重大战，即将来临。走GCG/GLP-1双靶点路线的玛仕度肽，9毫克组60周减掉了18.55%。研究显示，80周最高剂量组减重28.3%，BMI≥35的对照组，104周减重甚至到了30.3%。此外，医保几轮谈判下来，PD-1的年治疗费用已经不要3万元，这已经不能单纯的算是降价了。疗效类似，再牛的“药王”也扛不住降价的仿制药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8uwIsXpkDir","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MEDI","PJP","FXH","RSPH","LU1169589451.USD","THNR","XLVI","BK4023","NBDS","FHLC","NVOC","LU1169590202.USD","PD","PINK","CURE","TRUH","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652726614","title":"A股減肥藥板塊低開高走，海正藥業漲停，博騰股份升逾4%，翰宇藥業、眾生藥業、皓元醫藥、恒瑞醫藥等個股跟漲。","url":"https://stock-news.laohu8.com/highlight/detail?id=2652726614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652726614?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 10:04","pubTimestamp":1784513089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FHLC","RSPH","PINK","IYH","CURE","NBDS","FXH","MEDI","PJP","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651471109","title":"HCA醫療下調年度營收預期後，醫院運營商股價集體下跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651471109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651471109?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 21:37","pubTimestamp":1784036274,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0211328371.USD","PINK","LU2355687059.USD","IE00B3S45H60.SGD","LU0211327993.USD","LU0310799852.SGD","BK4588","CURE","IHF","LU0985489474.SGD","LU1119994496.HKD","LU0878866978.SGD","BK4585","LU2244417387.USD","SG9999014039.USD","LU0130102774.USD","LU0128525929.USD","SG9999014013.SGD","BK4185","LU0433182093.SGD","LU1150488218.USD","LU1201861249.SGD","LU0187121727.USD","LU1267930573.SGD","LU1489326972.SGD","LU0868494617.USD","BK4504","LU1150488135.SGD","SG9999014005.SGD","LU0310800379.SGD","LU0980610538.SGD","XHS","HCA","SG9999014021.USD","LU0203347892.USD","LU0029864427.USD","LU0114720955.EUR","LU1267930490.SGD","LU0203345920.USD","IE00B775SV38.USD","LU0708994859.HKD","LU0648001328.SGD","LU1261432733.SGD","LU0882574055.USD","LU1084165304.USD","LU0068578508.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651112380","title":"「筆帽」專利訴訟背後：減肥藥帶火百億注射筆賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2651112380","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651112380?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 21:23","pubTimestamp":1783948980,"startTime":"0","endTime":"0","summary":"一起“笔帽”专利纠纷，揭开GLP-1注射笔百亿市场的一角。7月10日，银诺医药（2591.HK）通过官方微信公众号发布情况说明，称公司作为被告涉及一起实用新型专利侵权诉讼，原告为苏州嘉树生物医疗科技有限公司（简称“苏州嘉树”），诉讼的核心问题不是银诺医药GLP-1产品依苏帕格鲁肽α注射液本身，而是产品配套使用的预充式注射笔中笔帽是否存在侵权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607133804157469.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607133804157469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CURE","ITAN","FXH","PJP","PINK","RSPH","NBDS","PATN","IYH","THNR","MEDI","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115402","title":"創新醫療器械審批有了綠色通道 國產醫療器械為全球提供中國方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115402?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 19:05","pubTimestamp":1783940733,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LGHT","PTH","RSPH","MEDX","BMED","PINK","XHE","FHLC","IHI","IBRN","GDOC","MDEV","HART","RXD","PSCH","BK4585","BK4588","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651853167","title":"減肥藥板塊短線拉升，爭光股份升逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651853167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651853167?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 10:24","pubTimestamp":1783909464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FXH","PJP","RSPH","NBDS","IYH","MEDI","THNR","PINK","CURE","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650015959","title":"一款「芭比藥」的粉色妙妙之旅","url":"https://stock-news.laohu8.com/highlight/detail?id=2650015959","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650015959?lang=zh_tw&edition=fundamental","pubTime":"2026-07-11 17:19","pubTimestamp":1783761540,"startTime":"0","endTime":"0","summary":"但他们所不知道的是，“芭比药”的研发历史相当曲折，简直可以当小说看了。于是，布美诺肽就代替MT-Ⅱ，开始了粉色的妙妙之旅。虽然这功效并没有获得监管批准，而科普媒体也一再表示，它属于“非法药物”，甚至可能会导致皮肤黑痣乃至癌变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656185805&idx=3&sn=eb6c8d7e61b86e01bf61cbe1b1fe3a32&chksm=6747443a3d6abd9cf22033ac33b7440908b12731394274e4f26387986b2b7a36cfc840bfbb67&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["FHLC","PJP","THNR","PINK","EPP","CURE","NBDS","RSPH","FXH","IYH","BK4582","MEDI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}